LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer.

Donatella Delle CaveSilvia BuonaiutoBruno SainzMarco FantuzMaria ManginiAlessandro CarrerAnnalisa Di DomenicoTea Teresa IavazzoGennaro AndolfiCarme CortinaMarta SevillanoChristopher HeeschenVincenza ColonnaMarco CoronaAntonio CucciardiMartina Di GuidaEduard BatlleAnnachiara De LucaEnza Lonardo

Published in: Journal of experimental & clinical cancer research : CR (2022)

We have identified a highly metastatic subpopulation of TICs marked by LAMC2. Strategies aimed at targeting the LAMC2 population may be effective in reducing tumor aggressiveness in PDAC patients. Our results prompt further study of this TIC population in pancreatic cancer and exploration as a potential therapeutic target and/or biomarker.

Keyphrases

end stage renal disease
ejection fraction
small cell lung cancer
squamous cell carcinoma
prognostic factors
peritoneal dialysis
cell therapy
mesenchymal stem cells
bone marrow